We assessed whether frozen recombinant tissue plasminogen activator (rt-PA)
remains stable and sterile for up to 22 weeks at -30 degrees C. Our findin
gs confirm that rt-PA is a cost-effective alternative to urokinase for rest
oring patency to occluded central venous catheters.